Bortezomib and Dexamethasone (BD) Regimen for Multiple Myeloma

Matthew R. Rutledge

doi:10.1310/hpj4501-33

Abstract

The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy, and to the agents, commercially available and investigational, used to treat malignant diseases.

Authors

Matthew R. Rutledge#1

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

unpaywall

Confidence 95%

datacite

Confidence 0%

Referenced works

View all references →

No local reference links have been materialized yet.

Cited by

View all cited-by records →

No local citing links have been materialized yet.

External reference records

Unresolved referenced work

2006

10.1111/j.1365-2141.2005.05540.x

10.1111/j.1365-2141.2009.07803.x

Unresolved referenced work

Kept as external metadata until matched

10.1182/blood.v108.11.56.56

10.1182/blood.v108.11.796.796

10.1111/j.1365-2141.2008.07409.x

10.1111/j.1365-2141.2004.05188.x

Unresolved referenced work

Kept as external metadata until matched

10.1532/ijh97.07030

10.1200/jco.2007.12.3323

10.3816/clm.2006.n.050

Bortezomib and Dexamethasone (BD) Regimen for Multiple Myeloma

Referenced works

Cited by

External reference records

Additional external references